Arrowhead Research just announced the publication of a scientific paper detailing its fundamentally new DPC delivery approach (discusse...

[ please note the changes below after I discovered that I missed the last claim amendments, as correctly pointed out by a commenter ] ...

Transthyretin-mediated amyloidosis has become the single-most important factor for the 3-5 year valuation of certainly Alnylam, and pos...

A somewhat vexing problem with DNA-directed RNAi (ddRNAi) has been the heterogeneous mixture of small RNAs generated from a typical expre...

When Tekmira filed its lawsuit against Alnylam in March 2011, it found itself in an impossible position: Alnylam’s apparent mis-use of S...

Today, I would like to post excerpts from Alnylam's most recent quarterly filing with the SEC (10-Q, here ), comments that are relate...

Attending the Oligonucleotide Therapeutics Society meeting last week in Boston, I could sense a new bullishness around RNAi Therapeutic...